Business Wire

UNC Health Care System Selects ARxIUM for Expansion of Shared Services Center

Del

ARxIUM, an industry-leading developer of pharmacy automation, workflow and consulting solutions, today announced the company was selected as vendor of choice by UNC Health Care to further centralize and increase pharmacy operations of its Shared Services Center. The expanded partnership includes the installation of ARxIUM’s pharmacy inventory management software, RxWorks Pro, and high-density inventory storage, FastFind carousels, to better serve pharmacies in the health system’s network.

RxWorks Pro’s integrated, web-based ordering provides UNC Health Care a comprehensive application to manage medication fulfillment of satellite and clinic pharmacy sites. In addition, its business intelligence feature includes customizable dashboards and reporting options that offer better management of medication inventories and real-time response to pharmacy demands. More importantly, the software interoperates with enterprise platforms and other manufacturers’ pharmacy systems and connects with the FastFind carousels to effectively manage medication supplies.

“We are excited by the opportunity to expand our partnership with UNC Health Care and grow its Shared Services Center into one of the most advanced health system pharmacies in the world,” said Dr. Niels Erik Hansen, president and CEO of ARxIUM. “Their innovative, system-wide approach and pharmacy model is the gold standard for other health systems that are looking to centralize and optimize operations. Our multi-phase engagement will result in a highly automated, interoperable Shared Services Center that can effectively onboard and serve pharmacies and clinics throughout the health system.”

ARxIUM’s plan for the UNC Shared Services Center also includes low-density, fixed shelving for higher demand drugs, FastFind carousels for slower moving medications and sortation to manage material flow. FastFind uses a pharmacy’s vertical height to increase the number of items stored in the same footprint by up to 60 percent. The carousel provides barcode scanning, pick-to-light technology and a drug database to enhance patient safety, and has the ability to purchase medications to replenish inventories. The new applications and equipment will complement UNC Health Care’s usage of other ARxIUM systems, including FastPak Elite, an oral solid pouch packaging system, and OptiFill, a high-volume medication fulfillment solution.

“We selected ARxIUM to expand our Shared Services Center because we rely upon their team to provide custom-configured timely solutions,” said Rowell Daniels, system vice president, pharmacy at UNC Health Care System. “Our ongoing partnership has been a collaborative effort that is focused on developing technologies and integrating systems that adapt to our needs. RxWorks, for example, has the ability to handle complex pharmacy situations and improves our cost savings and productivity.”

The UNC Health Care partnership represents the company’s newest approach to servicing its customers. The company consulted with the health system on the future state of its pharmacy operations and helped define the supply delivery system of medications between its hospitals, clinics and Shared Services Center. Additionally, ARxIUM created project specifications and a business case that was technology agnostic, and it recommended pharmacy equipment and automation to achieve patient care and operational objectives. This collaborative, consultative approach is especially important for pharmacies that are considering centralizing or consolidating operations and it serves as a substantial differentiator from competing pharmacy automation providers.

About ARxIUM
Based in Winnipeg, Manitoba and Buffalo Grove, Illinois, ARxIUM is an industry-leading developer of pharmacy automation, workflow and consulting solutions that improve safety, productivity and workflow. The company provides solutions to shared service centers and health system, hospital, long-term care, retail and government pharmacies. ARxIUM is the developer of the only fully automated IV compounding system in the market today, and offers automated packaging, dispensing, vial filling and high volume systems. In addition, the company provides inventory management, scheduling and workflow software, technical consulting, and system implementation assistance, among other services. ARxIUM is also the creator of the Pharmacy 4.0 approach, which seamlessly converges clinical pharmacy, central production and automation advancements into fully automated, interactive data processes. The approach allows pharmacies to better monitor and react in real-time to address patient care and medication delivery demands. For more information, visit www.arxium.com.

About UNC Health Care
UNC Health Care is an integrated health care system comprised of UNC Hospitals and its provider network, UNC Faculty Physicians, UNC Physicians Network, the clinical patient care programs of the UNC School of Medicine and nine other hospitals and hospital systems across the state. Additional hospital entities include UNC Rex Healthcare, Chatham Hospital, Johnston Health, Pardee Hospital, High Point Regional Health, Caldwell Memorial, Nash Health Care, Wayne Memorial, UNC Lenoir Health Care and UNC Rockingham. For more information, visit www.unchealthcare.org.

Contact information

Cookerly Public Relations
Cory Stewart, 404-816-2037
cory@cookerly.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 06:00:00 CETPressemelding

Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team

Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA25.3.2019 23:00:00 CETPressemelding

Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W

Game of Thrones Winter is Coming™ Launches Worldwide25.3.2019 23:00:00 CETPressemelding

Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi

bluebird bio Statement on European Regulatory Status of LentiGlobin™25.3.2019 22:40:00 CETPressemelding

A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 20:30:00 CETPressemelding

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in

AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 19:50:00 CETPressemelding

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin